SHARE

Axxess Pharma Inc (OTCMKTS:AXXE)’s subsidiary unit informed that they expect to register strong revenue in 2H2015. So far, 2015 has been a good year with completion of aggressive marketing plans and getting approvals for distribution of all-natural Tapout supplements. Axxess Pharma is a licensee for Tapout.

The developments

Axxess Pharma reported that it expanded product line with addition of peanut butter bars, chocolate protein bars, organic proteins and protein powders. All the expansion measures conclude at a time when already the supermarkets are set to sell its Tapout products in stores across the country.

In addition to expanding the product line, the company is also taking substantial measures to complete the financial audits so as to list on the OTCQB exchange. The audits are expected to be closed in the coming weeks following which the company will be able to up list on the OTCQB. It is important to note that OTCQB exchange is a more liquid platform and is accepted by the reputed financial institutions as well as Wall Street brokers.

The expert view

Dr. Bagi, the President stated that Axxess Pharma management is excited to have achieved the defined goals. It will not only lead to expansion of products but also move the brand into global markets. It will be made possible with help of new partners. Dr. Bagi further added that The TapouT line is another name of natural and productive fitness and sports options. They deliver a great synergy for nutrition houses, well fitness centers, and supermarkets.

Dr. Bagi mentioned that FY2015 continues to be a remarkable year for Axxess. The company is aiming for expansion of marketing and sales program in 2016. Also, the financial audits are expected to end in coming weeks after which Axxess Pharma would quickly uplist on OTCQB.

In last trading session, the stock price of Axxess Pharma Inc (OTCMKTS:AXXE) gained more than 3% to close the trading session at $0.0330. The gains came at a share volume of 1.44 million compared to average share volume of 978, 851.

LEAVE A REPLY